Processing

Please wait...

Settings

Settings

Goto Application

1. CA2422013 - SUBSTITUTED UREA NEUROPEPTIDE Y Y5 RECEPTOR ANTAGONISTS

Office
Canada
Application Number 2422013
Application Date 12.09.2001
Publication Number 2422013
Publication Date 21.03.2002
Publication Kind A1
IPC
C07D 211/58
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
211Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
04with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
06having no double bonds between ring members or between ring members and non-ring members
36with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
56Nitrogen atoms
58attached in position 4
A61K 31/4465
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
44Non-condensed pyridines; Hydrogenated derivatives thereof
445Non-condensed piperidines, e.g. piperocaine
4465only substituted in position 4
A61K 31/4525
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
44Non-condensed pyridines; Hydrogenated derivatives thereof
445Non-condensed piperidines, e.g. piperocaine
4523containing further heterocyclic ring systems
4525containing a five-membered ring with oxygen as a ring hetero atom
A61K 31/4535
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
44Non-condensed pyridines; Hydrogenated derivatives thereof
445Non-condensed piperidines, e.g. piperocaine
4523containing further heterocyclic ring systems
4535containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
A61K 31/4545
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
44Non-condensed pyridines; Hydrogenated derivatives thereof
445Non-condensed piperidines, e.g. piperocaine
4523containing further heterocyclic ring systems
4545containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
A61P 3/04
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
3Drugs for disorders of the metabolism
04Anorexiants; Antiobesity agents
CPC
A61P 1/14
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
1Drugs for disorders of the alimentary tract or the digestive system
14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
A61P 1/16
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
1Drugs for disorders of the alimentary tract or the digestive system
16for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
A61P 3/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
3Drugs for disorders of the metabolism
A61P 3/04
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
3Drugs for disorders of the metabolism
04Anorexiants; Antiobesity agents
A61P 3/06
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
3Drugs for disorders of the metabolism
06Antihyperlipidemics
A61P 3/10
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
3Drugs for disorders of the metabolism
08for glucose homeostasis
10for hyperglycaemia, e.g. antidiabetics
Applicants SCHERING CORPORATION
Inventors GREENLEE, WILLIAM J.
HUANG, YING
KELLY, JOSEPH M.
MCCOMBIE, STUART W.
STAMFORD, ANDREW W.
WU, YUSHENG
Priority Data 60/232,255 14.09.2000 US
Title
(EN) SUBSTITUTED UREA NEUROPEPTIDE Y Y5 RECEPTOR ANTAGONISTS
(FR) ANTAGONISTES DU RECEPTEUR Y.Y5 DE NEUROPEPTIDE D'UREASE SUBSTITUE
Abstract
(EN)
Compounds represented by structural formula (I) including its N-oxides wherein Y is (a) or (b); R1~ is H or (C~1-C~6)alkyl; R2~ is H,(C~1-C~6)alkyl,(C~3- C~9)cycloalkyl or (C~3-C~7)cycloalkyl(C~1-C~6)alkyl; R3~ is (c), (d), (e), (f), (g), (h) or (i); R4~ is 1-3 substituents independently selected from the group consisting of H, -OH, halogen, haloalkyl,(C~1-C~6) alkyl, (C~3-C~7) cycloalkyl, (C~3-C~7) cycloalkyl (C~1-C~6) alkyl, -CN, -O(C~1-C~6) alkyl, - O(C~3-C~7) cycloalkyl, -O(C~1-C~6) alkyl (C~3-C~7) cycloalkyl, -S(C~1-C~6) alkyl, -S(C~3-C~7) cycloalkyl, -S(C~1-C~6) alkyl(C~3-C~7) cycloalkyl, -NH~2, - NR9~R10~, -NO~2, -CONH~2, -CONR9~R10~ and NR2~COR10~; or where applicable, a geometric or optical isomer or a racemic mixture thereof, are claimed, as well as additional novel compounds; also claimed are pharmaceutical compositions and methods of using the aforesaid compounds in the treatment of obesity, eating disorders such as hyperphagia and diabetes.